Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin

Archives of Virology

Volumn 161, Issue 9, 2016, Pages 2473-2480

  Abdelraheem, Wedad M ^a   Hassuna, Noha A ^a   Abuloyoun, Sahar M ^a   Abdel Ghany, Hend M ^a   Rizk, Hazem A ^a   Abdelwahab, Sayed F ^a,b  

^a Minia University   (Egypt)

^b TAIF UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; INTERLEUKIN 10; INTERLEUKIN 18; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; EGYPT; EPIDEMIOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; EGYPT; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-18; MALE; MIDDLE AGED; MUTATION; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84976407790     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-016-2948-y     Document Type: Article

References (41)

1. Abbas Z, Moatter T, Hussainy A, Jafri W (2005) Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 11:6656–6661
2. Abdelwahab S, Rewisha E, Hashem M, Sobhy M, Galal I, Allam WR, Mikhail N, Galal G, El-Tabbakh M, El-Kamary SS, Waked I, Strickland GT (2012) Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre. Trans Royal Soc Trop Med Hyg 106:98–103
3. Afzal MS, Tahir S, Salman A, Baig TA, Shafi T, Zaidi NU, Qadri I (2011) Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Cties 5:473–479
4. Afzal MS, Anjum S, Zaidi NU (2013) Effect of Functional Interleukin-10 Polymorphism on Pegylated Interferon-alpha Plus Ribavirin Therapy Response in Chronic Hepatitis C Virus Patients Infected With 3a Genotype in Pakistani Population. Hepat Mon 13:e10274
5. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY, Negro F (2013) IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 20:59–64
6. Bahgat NA, Kamal MM, Abdelaziz AO, Mohye MA, Shousha HI, Ahmed MM, Elbaz TM, Nabil MM (2015) Interferon-gamma and Interleukin-10 Gene Polymorphisms are not Predictors of Chronic Hepatitis C (Genotype-4) Disease Progression. Asian Pac J Cancer Preven APJCP 16:5025–5030
7. Bouzgarrou N, Hassen E, Schvoerer E, Stoll-Keller F, Bahri O, Gabbouj S, Cheikh I, Maamouri N, Mammi N, Saffar H, Trabelsi A, Triki H, Chouchane L (2008) Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol 80:607–614
8. Chuang JY, Yang SS, Lu YT, Hsieh YY, Chen CY, Chang SC, Chang CS, Yeh HZ, Kao JH (2009) IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Digest Liver Dis Off J Italian Soc Gastroenterol Italian Assoc Study Liver 41:424–430
9. da Silva NM, Germano FN, Vidales-Braz BM, Carmo Zanella R, dos Santos DM, Lobato R, de Martinez AM (2015) Polymorphisms of IL-10 gene in patients infected with HCV under antiviral treatment in southern Brazil. Cytokine 73:253–257
10. Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-dweik N, Yakoob R, Pasic F, Almohanadi M, Alejji K, Abdelmola A, Butt M (2013) The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology 444:292–300
11. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE (1999) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526–530
12. El Bassat H, Ali LA, El-Din RAA, Hasby E, Shahbah A (2013) Serum level of interleukin-10 with its gene polymorphism can be predictors of response to treatment in Egyptian patients with chronic hepatitis C virus. Egypt J Med Human Genet 14:227–233
13. Farid S, Rashid L, Swelam S (2013) The role of interleukin-18 promoter polymorphisms (-607 C/A and 137 G/C) in determining HCV clearance or persistence. Egypt J Hosp Med 50:141–149
14. Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, Wang SY, Tong LX (2009) Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 15:5610–5619
15. Guerra J, Garenne M, Mohamed MK, Fontanet A (2012) HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 19:560–567
16. Haas SL, Weiss C, Bugert P, Gundt J, Witt H, Singer MV, Berg T, Bocker U (2009) Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. J Clin Immunol 29:620–628
17. Helal SF, Gomaa HE, Thabet EH, Younan MA, Helmy NA (2014) Impact of IL-10 (-1082) promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol 7:19–24
18. Imran M, Manzoor S, Parvaiz F (2014) Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population. Viral Immunol 27:404–411
19. Irshad M, Ansari MA, Singh A, Nag P, Raghvendra L, Singh S, Badhal SS (2010) HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment. Hepato-Gastroenterol 57:1529–1538
20. Kariz S, Petrovic D (2011) Interleukin-18 promoter gene polymorphisms are not associated with myocardial infarction in type 2 diabetes in Slovenia. Balkan J Med Genet BJMG 14:3–9
21. Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, Goldin R, Hill AV, Thomas HC, Thursz MR (2003) Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 55:362–369
22. Ksiaa Cheikhrouhou L, Sfar I, Aounallah-Skhiri H, Aouadi H, Jendoubi-Ayed S, Ben Abdallah T, Ayed K, Lakhoua-Gorgi Y (2011) Cytokine and apoptosis gene polymorphisms influence the outcome of hepatitis C virus infection. Hepato Pancreat Dis Int HBPD INT 10:280–288
23. Kusumoto K, Uto H, Hayashi K, Takahama Y, Nakao H, Suruki R, Stuver SO, Ido A, Tsubouchi H (2006) Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 34:24–31
24. Liang XH, Cheung W, Heng CK, Wang DY (2005) Reduced transcriptional activity in individuals with IL-18 gene variants detected from functional but not association study. Biochem Biophys Res Commun 338:736–741
25. Lu YL, Wu X, Huang HL, Dai LC (2010) Allele polymorphisms of interleukin-10 and hepatitis B, C virus infection. Chin Med J 123:1338–1344
26. Mandour M, Nemr N, Kishk R, Ahmed E (2014) Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients. Revista da Sociedade Brasileira de Medicina Tropical 47:137–142
27. Manohar K, Suneetha PV, Sukriti Pati NT, Gupta AC, Hissar S, Sakhuja P, Sarin SK (2009) Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients. Hepatol Int 3:371–377
28. Murata K, Yamamoto N, Kawakita T, Saito Y, Yamanaka Y, Sugimoto K, Shiraki K, Nakano T, Tameda Y (2005) Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. Hepato-Gastroenterol 52:547–551
29. Pár A, Kisfali P, Melegh B, Tornai I, Gervain J, Szalay F, Varga M, Papp M, Schuller J, Tusnádi A, Fehér J, Lengyel G, Nemes Z, Péterfi Z, Hunyady B, Vincze A, Pár G (2011) Cytokine (IL-10, IL-28B and LT-A) gene polymorphisms in chronic hepatitis C virus infection. Clin Exp Med J 5:9–19
30. Pasha HF, Radwan MI, Hagrass HA, Tantawy EA, Emara MH (2013) Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine 61:478–484
31. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Ann Rev Immunol 22:929–979
32. Ramos JA, Silva R, Hoffmann L, Ramos AL, Cabello PH, Urmenyi TP, Villella-Nogueira CA, Lewis-Ximenez L, Rondinelli E (2012) Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Res Notes 5:508
33. Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36:S35–S46
34. Shaker OG, Sadik NA (2012) Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. J Gastroenterol Hepatol 27:1842–1849
35. Stattermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, Scherzer TM, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P (2014) Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Therapeut 39:104–111
36. Subbarayan PR, Sarkar M, Ardalan B (2002) Isolation of genomic DNA from human whole blood. BioTechniques 33(1231):1234
37. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T (2002) Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 35:937–946
38. Vecchiet J, Falasca K, Cacciatore P, Zingariello P, Dalessandro M, Marinopiccoli M, D’Amico E, Palazzi C, Petrarca C, Conti P, Pizzigallo E, Guagnano MT (2005) Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann Clin Lab Sci 35:415–422
39. Vidigal PG, Germer JJ, Zein NN (2002) Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 36:271–277
40. Yang Y, Liu H (2015) Association between interleukin-18 gene promoter (-607C/A and -137G/C) polymorphisms and chronic hepatitis C virus infections: a meta-analysis. Meta gene 5:21–31
41. Zhang PA, Wu JM, Li Y, Yang XS (2005) Association of polymorphisms of interleukin-18 gene promoter region with chronic hepatitis B in Chinese Han population. World J Gastroenterol 11:1594–1598